648 related articles for article (PubMed ID: 27002676)
41. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
[TBL] [Abstract][Full Text] [Related]
42. Transjugular intrahepatic portosystemic shunt--role in treating intractable variceal bleeding, ascites, and hepatic hydrothorax.
LaBerge JM
Clin Liver Dis; 2006 Aug; 10(3):583-98, ix. PubMed ID: 17162229
[TBL] [Abstract][Full Text] [Related]
43. [Treatment of refractory hepatic encephalopathy associated with insertion of a transjugular intrahepatic portosystemic shunt through new endovascular techniques: a case report].
Martínez Moreno B; Bellot P; de España F; Palazón JM; Such J; Pérez-Mateo M
Gastroenterol Hepatol; 2011; 34(7):468-73. PubMed ID: 21652116
[TBL] [Abstract][Full Text] [Related]
44. Results of a retrospective multicenter trial of the Viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation.
Charon JP; Alaeddin FH; Pimpalwar SA; Fay DM; Olliff SP; Jackson RW; Edwards RD; Robertson IR; Rose JD; Moss JG
J Vasc Interv Radiol; 2004 Nov; 15(11):1219-30. PubMed ID: 15525740
[TBL] [Abstract][Full Text] [Related]
45. Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension.
Chen R; Luo L; Zhang YZ; Liu Z; Liu AL; Zhang YW
World J Gastroenterol; 2024 Apr; 30(13):1859-1870. PubMed ID: 38659484
[TBL] [Abstract][Full Text] [Related]
46. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
Colombato L
J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
[TBL] [Abstract][Full Text] [Related]
47. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial.
Perarnau JM; Le Gouge A; Nicolas C; d'Alteroche L; Borentain P; Saliba F; Minello A; Anty R; Chagneau-Derrode C; Bernard PH; Abergel A; Ollivier-Hourmand I; Gournay J; Ayoub J; Gaborit C; Rusch E; Giraudeau B;
J Hepatol; 2014 May; 60(5):962-8. PubMed ID: 24480619
[TBL] [Abstract][Full Text] [Related]
48. [TIPS - Transjugular intrahepatic portosystemic shunt. A review].
Carreiro G; da Luz Moreira A; Murad FF; Azevedo F; Coelho HS
Arq Gastroenterol; 2001; 38(1):69-80. PubMed ID: 11586999
[TBL] [Abstract][Full Text] [Related]
49. Transjugular intrahepatic portosystemic shunt following liver transplantation: can outcomes be predicted?
El Atrache M; Abouljoud M; Sharma S; Abbass AA; Yoshida A; Kim D; Kazimi M; Moonka D; Brown K
Clin Transplant; 2012; 26(4):657-61. PubMed ID: 22309034
[TBL] [Abstract][Full Text] [Related]
50. Transjugular intrahepatic portosystemic shunts: an update.
Rosado B; Kamath PS
Liver Transpl; 2003 Mar; 9(3):207-17. PubMed ID: 12619016
[TBL] [Abstract][Full Text] [Related]
51. The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension.
Hassoun Z; Pomier-Layrargues G
Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):1-4. PubMed ID: 15095845
[TBL] [Abstract][Full Text] [Related]
52. [Transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of complications of portal hypertension in patients with liver cirrhosis].
Grønbaek H; Astrup LB; Nielsen DT; Vilstrup H
Ugeskr Laeger; 2003 Jan; 165(5):439-42. PubMed ID: 12599838
[TBL] [Abstract][Full Text] [Related]
53. TIPS for management of refractory ascites: response and survival are both unpredictable.
Thuluvath PJ; Bal JS; Mitchell S; Lund G; Venbrux A
Dig Dis Sci; 2003 Mar; 48(3):542-50. PubMed ID: 12757168
[TBL] [Abstract][Full Text] [Related]
54. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy.
Pereira K; Carrion AF; Martin P; Vaheesan K; Salsamendi J; Doshi M; Yrizarry JM
Liver Int; 2015 Dec; 35(12):2487-94. PubMed ID: 26332169
[TBL] [Abstract][Full Text] [Related]
55. [TIPS--transjugular intrahepatic portosystemic shunt. Experiences from a recently started center].
Astrup LB; Grønbaek H; Redsted S; Nielsen DT; Vilstrup H
Ugeskr Laeger; 2003 Jan; 165(5):443-6. PubMed ID: 12599839
[TBL] [Abstract][Full Text] [Related]
56. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed.
Membreno F; Baez AL; Pandula R; Walser E; Lau DT
J Gastroenterol Hepatol; 2005 Mar; 20(3):474-81. PubMed ID: 15740494
[TBL] [Abstract][Full Text] [Related]
57. Clinical effects and complications of TIPS for portal hypertension due to cirrhosis: a single center.
Qin JP; Jiang MD; Tang W; Wu XL; Yao X; Zeng WZ; Xu H; He QW; Gu M
World J Gastroenterol; 2013 Nov; 19(44):8085-92. PubMed ID: 24307804
[TBL] [Abstract][Full Text] [Related]
58. Effects of transjugular intrahepatic portosystemic shunt treatment of patients with liver cirrhosis and portal hypertension: Case series.
Zheng D; Yu J; Li H; Gan H; Wang J; Jiang T; Ren H; Wu F
Medicine (Baltimore); 2021 Jul; 100(27):e26610. PubMed ID: 34232216
[TBL] [Abstract][Full Text] [Related]
59. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial.
Riggio O; Ridola L; Angeloni S; Cerini F; Pasquale C; Attili AF; Fanelli F; Merli M; Salvatori FM
J Hepatol; 2010 Aug; 53(2):267-72. PubMed ID: 20537753
[TBL] [Abstract][Full Text] [Related]
60. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis.
Han G; Qi X; He C; Yin Z; Wang J; Xia J; Yang Z; Bai M; Meng X; Niu J; Wu K; Fan D
J Hepatol; 2011 Jan; 54(1):78-88. PubMed ID: 20932597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
